Lenalidomide/Dexamethasone in High-Risk Smoldering Multiple Myeloma

Get Permission

Long-term follow-up in the phase III QuiRedex trial indicates continued benefit of lenalidomide (Revlimid)/dexamethasone vs observation in preventing disease progression in patients with high-risk smoldering multiple myeloma, as reported by Maria-Victoria Mateos, PhD, of Instituto de Biologia Molecular y Celular del Cancer, Salamanca, and colleagues in The Lancet Oncology.

In the open-label trial, conducted at 19 sites in Spain and 3 sites in Portugal, 119 patients (constituting the per-protocol population for efficacy analysis) were randomized between November 2007 and June 2010 to receive induction lenalidomide/dexamethasone followed by lenalidomide maintenance and dexamethasone at biologic progression during maintenance (n = 57) or observation (n = 62). At the time of first analysis in 2013, at a median follow-up of 45 months, median time to progression to symptomatic disease was not reached vs 21 months (hazard ratio [HR] = 0.18, P < .0001), and 3-year overall survival was 94% vs 80% (HR = 0.31, P = .03).

Current Analysis

In the current analysis, at median follow-up for surviving patients of 75 months, median time to disease progression was not reached vs 23 months (HR = 0.24, P < .0001), with disease progression occurring in 39% vs 86% of patients. Median overall survival from the time of study entry had not been reached in either group (HR = 0.43, P = .024). There was no significant difference between the groups in survival among patients who received subsequent treatment at disease progression (HR = 1.34, P = .50). Overall, 39% and 85% of patients received antimyeloma treatment after disease progression. Second primary malignancies occurred in 10% of the lenalidomide/dexamethasone group vs 2% of the observation group (P = .070).

The investigators concluded: “This study is, to our knowledge, the first randomised trial in which early treatment has been assessed in selected patients with high-risk smouldering multiple myeloma. Positive results from ongoing trials would support the use of early treatment for patients with high-risk disease in the near future.”

The study was funded by PETHEMA (Spanish Program for the Treatment of Hematologic Diseases).■

Mateos MV, et al: Lancet Oncol 17:1127-1136, 2016.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.